"Is it your understanding that the royalty only applies to CVD indication(s?) revenues?  Or are royalties payable on revenues from CKD, cognition, and all other indication as well?  TIA"

The original royalty situation was limited to the eligible revenue from ANY Resverlogix compound that was found to modulate the levels of apolipoprotein-AI (apo-AI) by a pre-stated threshhold. I think this thresshold was pre-determined in a cell culture model, such as HepG2 cells or primary human hepatocytes, treated with a fixed concentration of compound for a fixed time period and assayed by apo-AI mRNA or protein change. It does not matter if it the drug was being clinically developed for CVD, renal, cognition etc. Eligible revenue from ANY drug for ANY indication that met the apo-AI threshhold was subject to the royalty. 

The revised royalty situation removes this apo-AI requirement. So now ANY Resverlogix drug for ANY indication (not just CVD) that generates eligible revenue will be subject to the royalty. 

BearDownAZ